Clinical trials: Neovascular Macular Degeneration
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema
This is an observational study in which data already collected from participants with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) is studied.
- Trial name
- NCT06929143
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Japan
- Volunteers
- 3,000 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration
Development of an Optimal Algorithm for the Management of Patients With Retinal Pigment Epithelium Detachment in Neovascular Age-related Macular Degeneration Using Artificial Intelligence
The study involves the development of an algorithm for predicting anatomical and functional results of therapy with angiogenesis inhibitors in patients with retinal pigment epithelium detachments in neovascular age-related…
- Trial name
- NCT05208931
- Testing
- Anti-vascular endothelial growth factor therapy
- Where
- Russia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The S.N. Fyodorov Eye Microsurgery State Institution
Wet Age Related Macular Degeneration, Neovascular (Wet) Age-Related Macular Degeneration
Evaluation of PAN-90806 Eye Drops in Healthy Subjects
The goal of this clinical trial is to learn about the safety, tolerability, and systemic pharmacokinetics of PAN-90806 eye drops in healthy adults.
- Trial name
- NCT07764965
- Testing
- PAN-90806 Ophthalmic Solution, Vehicle Ophthalmic Solution
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Neovascular Age-related Macular Degeneration
Retinal Pigment Epithelial Characteristics in Eyes With Neovascular Age-related Macular Degeneration Following Long-term Treatment With Anti Neovascular Endothelial Growth Factor
Purpose: To assess retinal pigment epithelial (RPE) and retinal structural changes in eyes with neovascular age-related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (anti-VEGF) during long-term…
- Trial name
- NCT03679156
- Testing
- OCT
- Volunteers
- 18 people
- Sponsor
- Hospital Hietzing
Neovascular Age-related Macular Degeneration
Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab
Title: Intravitreal aflibercept (VEGF Trap-Eye) in neovascular age-related macular degeneration with limited response to ranibizumab Purpose: The purpose of this investigator initiated study is to identify the duration of…
- Trial name
- NCT02309281
- Testing
- aflibercept 2mg
- Volunteers
- 33 people
- Sponsor
- Vista Klinik
Age-related Macular Degeneration
Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and…
- Trial name
- NCT06458595
- Testing
- KH658
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
Neovascular Age Related Macular Degeneration
A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)
Study Design This is a Single-center, Phase I/II placebo-controlled study to assess the safety and efficacy of PRL3-zumab in patients with Neovascular Age-related Macular Degeneration (nAMD).
- Trial name
- NCT07547228
- Testing
- PRL3-ZUMAB, Normal Saline (0.9% Sodium Chloride)
- Where
- Singapore
- Volunteers
- 15 people
- Sponsor
- Intra-IMMUSG Pte Ltd
Neovascular(Wet) Age Related Macular Degeneration
A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration
This is a multicenter, randomized, double-blind, active-controlled, parallel group, Phase III Clinical Trial To Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of CKD-701 and Lucentis® in Patients with…
- Trial name
- NCT04857177
- Testing
- CKD-701, Lucentis®
- Where
- South Korea
- Volunteers
- 312 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Wet Macular Degeneration
The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy
A study investigating the ability of OCTA imaging technology to identify and analyze untreated type 1, 2, and 3 neovascular membrane lesions in treatment naive patients with exudative macular degeneration, as well as…
- Trial name
- IAI-OCTA (NCT03022292)
- Testing
- Aflibercept Ophthalmic, optovue angiovue
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, Los Angeles
Macular Degeneration
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
- Trial name
- NCT02462486
- Testing
- Abicipar Pegol, Ranibizumab
- Where
- 187 sites in United States, Australia and 14 more
- Volunteers
- 949 people
- Sponsor
- Allergan
Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD)
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4…
- Conditions
- Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
- Trial name
- NCT06664502
- Testing
- EYE201
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 38 people
- Sponsor
- EyeBiotech Ltd.
Neovascular Age-related Macular Degeneration
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.
- Trial name
- Sightspire (NCT06847542)
- Testing
- Susvimo PDS Implant, Ranibizumab
- Where
- 61 sites in Austria, Czechia and 11 more
- Volunteers
- 250 people
- Sponsor
- Hoffmann-La Roche
Macular Degeneration
VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)
This study will assess the efficacy and safety of intravitreally (IVT), i.e. directly into the eye administered VEGF Trap-Eye compared with photodynamic therapy (PDT) on visual function in Chinese subjects with age-related…
- Trial name
- NCT01482910
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Visudyne
- Where
- 14 sites in China
- Volunteers
- 304 people
- Sponsor
- Bayer
Neovascular Age-Related Macular Degeneration
Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD
To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.
- Trial name
- NCT00370370
- Testing
- bevacizumab, bevacizumab + triamcinolone acetonide
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Age-Related Macular Degeneration, Choroidal Neovascularization
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
The primary purpose of this study is to assess the safety \& tolerability of an investigational drug 20089 TA (6.9 mg or 13.8 mg) when used adjunctively with Lucentis 0.5 mg in subjects with sub-foveal neovascular AMD.
- Trial name
- 20089/Combo (NCT01175395)
- Testing
- IBI-20089/Lucentis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Illinois Chicago
Neovascular Age-related Macular Degeneration
The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study
Neovascular age-related macular degeneration (AMD) is the leading cause of severe vision loss in the Western world. Intravitreal ranibizumab has recently become the treatment of choice for neovascular (AMD).
- Trial name
- NCT00599222
- Testing
- ranibizumab, TTT
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Anders Kvanta
Age Related Macular Degeneration (ARMD)
Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®
This is a randomized, double-blind, comparative, parallel group study of the efficacy, safety pharmacokinetics, and immunogenicity of GNR-067 and Lucentis® in patients with neovascular (wet) age-related macular degeneration.
- Trial name
- NAP (NCT04667039)
- Testing
- GNR-067, Lucentis®
- Where
- 9 sites in Russia
- Volunteers
- 408 people
- Sponsor
- AO GENERIUM
Macular Degeneration
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
This is a Phase II multicenter, dose-ranging, randomized, active treatment (monthly ITV injection)-controlled study to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered through the Implant using three…
- Trial name
- LADDER (NCT02510794)
- Testing
- Ranibizumab
- Where
- 50 sites in United States
- Volunteers
- 225 people
- Sponsor
- Genentech, Inc.
Neovascular Age-related Macular Degeneration
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).
- Trial name
- Belvedere (NCT04853251)
- Testing
- PDS Implant With Ranibizumab 100 mg/ml, LUCENTIS (Ranibizumab Injection)
- Where
- 40 sites in United States
- Volunteers
- 188 people
- Sponsor
- Genentech, Inc.
Neovascular Age-Related Macular Degeneration
Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD
The primary objective is to assess the safety of intravitreal (IVT) Zimura® administered in combination with anti-VEGF Therapy (AVASTIN®, EYLEA®, OR LUCENTIS®) in anti-VEGF treatment experienced subjects with neovascular…
- Trial name
- NCT05571267
- Testing
- Avacincaptad Pegol, Avastin, Lucentis
- Volunteers
- 1 people
- Sponsor
- IVERIC bio, Inc.